UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions
Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
